% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lalos:298919,
      author       = {F. Lalos and D. Flühs and M. Guberina and N. Bornfeld and
                      M. Stuschke$^*$ and W. Sauerwein and N. E. Bechrakis},
      title        = {{T}reatment-{R}elated {C}omplications and {F}unctional
                      {R}esults after {R}uthenium-106 {B}rachytherapy in {S}mall
                      to {M}edium {S}ize {U}veal {M}elanomas ({P}art 2).
                      [{B}ehandlungsbedingte {K}omplikationen und funktionelle
                      {E}rgebnisse nach {R}uthenium-106-{B}rachytherapie bei
                      kleinen bis mittelgroßen {A}derhautmelanomen ({T}eil 2)].},
      journal      = {Klinische Monatsblätter für Augenheilkunde},
      volume       = {242},
      number       = {2},
      issn         = {0023-2165},
      address      = {Stuttgart},
      publisher    = {Thieme},
      reportid     = {DKFZ-2025-00355},
      pages        = {116 - 126},
      year         = {2025},
      abstract     = {To analyze the treatment-related complications after
                      ruthenium-106 brachytherapy in patients with uveal melanoma
                      in terms of radiation-induced optic neuropathy, maculopathy
                      and retinopathy, radiation-related vitreous hemorrhage, and
                      retinal detachment, as well as secondary glaucoma and
                      radiogenic cataract. In addition, the course of visual
                      acuity was analyzed.This retrospective study included 608
                      patients treated with ruthenium-106 brachytherapy between
                      January 2008 and December 2010 at the Department of
                      Ophthalmology, University Hospital Essen. The follow-up time
                      was 11 years. The occurrence of the radiation-induced
                      complications was analyzed using the Kaplan-Meier method.
                      Cox regression was used for univariate and multivariate risk
                      factor analyses. Hazard ratios were calculated for each
                      variable.Regarding the complications, $34\%$ (N = 207) of
                      the patients had no reported side effects or complications
                      during follow-up. Radiation optic neuropathy was observed in
                      $18.8\%$ (N = 114) of the patients, with a median time to
                      onset of 16 months (range: 3 - 78 months). Radiation
                      maculopathy occurred in $8.2\%$ (N = 50) after a median time
                      of 17 months (range: 3 - 67 months). Radiation retinopathy
                      was observed in $20.1\%$ (N = 122), with a median time to
                      onset of 21 months (range: 6 - 67 months). Secondary
                      glaucoma developed in $9.7\%$ of the patients (N = 53) and
                      radiogenic cataract in $46.8\%$ (N = 227). Vitreous
                      hemorrhage $(11.8\%,$ N = 72) and scleral necrosis $(2.1\%,$
                      N = 13) occurred relatively rarely.The observed radiogenic
                      complication rate is comparable with that reported in
                      previous studies.},
      keywords     = {Humans / Uveal Neoplasms: radiotherapy / Brachytherapy:
                      adverse effects / Brachytherapy: methods / Male / Female /
                      Melanoma: radiotherapy / Middle Aged / Radiation Injuries:
                      etiology / Ruthenium Radioisotopes: therapeutic use / Aged /
                      Adult / Retrospective Studies / Treatment Outcome / Aged, 80
                      and over / Young Adult / Risk Factors / Comorbidity /
                      Adolescent / Vision Disorders: etiology / Incidence /
                      Prevalence / Visual Acuity: radiation effects / Ruthenium
                      Radioisotopes (NLM Chemicals) / Ruthenium-106 (NLM
                      Chemicals)},
      cin          = {ED01},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38395138},
      doi          = {10.1055/a-2275-5575},
      url          = {https://inrepo02.dkfz.de/record/298919},
}